search
Back to results

Needle Procedures Success Rate After Application of Ralydan vs EMLA in Children

Primary Purpose

Procedural Pain Relief

Status
Completed
Phase
Phase 3
Locations
Italy
Study Type
Interventional
Intervention
Lidocaine/Tetracaine patch
Lidocaine/Prilocaine cream
Sponsored by
IRCCS Burlo Garofolo
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Procedural Pain Relief focused on measuring Ralydan, EMLA cream, Procedural pain, Phlebotomy, Child

Eligibility Criteria

3 Years - 10 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 3 to 10 years
  • Need for peripheral IV line or venipuncture
  • Informed consent signed by parents or legal guardians

Exclusion Criteria:

  • Need for emergency care
  • Known allergy or sensitivity to local anesthetics

Sites / Locations

  • Ospedale Pediatrico Pausilipon - Servizio di terapia del dolore e cure palliative
  • IRCCS Burlo Garofolo
  • Università degli studi di Padova - Centro Regionale Veneto di terapia del dolore e cure palliative pediatriche

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Lidocaine/Tetracaine patch (Ralydan)

Lidocaine/Prilocaine cream (EMLA)

Arm Description

Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure

EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure

Outcomes

Primary Outcome Measures

Success at the first attempt
Percentage of success at first attempt

Secondary Outcome Measures

Pain score
The pain during the procedure will be evaluate using pain rating scale appropriate for age
Adverse events
The number and the type of adverse events will be recorded

Full Information

First Posted
August 7, 2015
Last Updated
March 25, 2016
Sponsor
IRCCS Burlo Garofolo
search

1. Study Identification

Unique Protocol Identification Number
NCT02519660
Brief Title
Needle Procedures Success Rate After Application of Ralydan vs EMLA in Children
Official Title
Lidocaine/Tetracaine Patch (Ralydan) vs Lidocaine/Prilocaine Cream (EMLA) for Needle Related Procedures in Children: a Multicenter, Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2016
Overall Recruitment Status
Completed
Study Start Date
April 2015 (undefined)
Primary Completion Date
December 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
IRCCS Burlo Garofolo

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Needle-related procedures are among the most common sources of pain and distress for children in the health care setting. More than 50% of children reported pain during these procedures. The necessity for pain management during these procedures is well established. Topical anesthesia has been shown to be effective in managing needle-related pain. Eutectic mixture of local anaesthetic (EMLA) cream is the topical anesthetic most used. The application of this mixture of lidocaine and prilocaine reduce pain during needle procedures in children. To be effective EMLA cream must be applied for at least 60 minutes before needle procedure. This is the major limitation for its use in emergency settings. Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. There is evidence of pain relief after 30 minutes from its application. Only one randomized controlled trial compared the two topical anaesthetics in children during venipuncture and showed that Ralydan patch led to superior analgesia than EMLA cream, even if in this study the two anaesthetics were applied only for 35 minutes before needle procedure. No differences were found in success rate of the procedure and vein visibility. In adult patients, Ralydan and EMLA were equally effective in pain relief after 60 minutes from application. To the best of the investigators' knowledge there is no published study that compared needle procedure success rate in children and pain relief effectiveness of lidocaine/tetracaine patch and lidocaine/prilocaine cream, at time of their maximum analgesic effect. The aim of this study is to compare Ralydan patch and EMLA cream at time of their maximum analgesic effect (30 minutes vs 60 minutes), regard to needle procedure success rate at the first attempt and pain relief in children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Procedural Pain Relief
Keywords
Ralydan, EMLA cream, Procedural pain, Phlebotomy, Child

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
339 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Lidocaine/Tetracaine patch (Ralydan)
Arm Type
Experimental
Arm Description
Ralydan patch is a drug delivery system designed to release local anaesthetics (lidocaine and tetracaine) through the skin. It is applied in the site of venipuncture 30 minutes before needle procedure
Arm Title
Lidocaine/Prilocaine cream (EMLA)
Arm Type
Active Comparator
Arm Description
EMLA cream is an eutectic mixture of local anaesthetic (lidocaine, prilocaine). It is applied in the site of venipuncture 60 minutes before needle procedure
Intervention Type
Drug
Intervention Name(s)
Lidocaine/Tetracaine patch
Other Intervention Name(s)
Ralydan
Intervention Type
Drug
Intervention Name(s)
Lidocaine/Prilocaine cream
Other Intervention Name(s)
EMLA
Primary Outcome Measure Information:
Title
Success at the first attempt
Description
Percentage of success at first attempt
Time Frame
Intraoperative
Secondary Outcome Measure Information:
Title
Pain score
Description
The pain during the procedure will be evaluate using pain rating scale appropriate for age
Time Frame
Intraoperative
Title
Adverse events
Description
The number and the type of adverse events will be recorded
Time Frame
Up to 15 minutes after the procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
3 Years
Maximum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 3 to 10 years Need for peripheral IV line or venipuncture Informed consent signed by parents or legal guardians Exclusion Criteria: Need for emergency care Known allergy or sensitivity to local anesthetics
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Egidio Barbi, MD
Organizational Affiliation
IRCCS Burlo Garofolo, Trieste, Italy
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Elena Neri, MD
Organizational Affiliation
IRCCS Burlo Garofolo, Trieste, Italy
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Giorgio Cozzi, MD
Organizational Affiliation
IRCCS Burlo Garofolo, Trieste, Italy
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ospedale Pediatrico Pausilipon - Servizio di terapia del dolore e cure palliative
City
Napoli
State/Province
Campania
ZIP/Postal Code
80121
Country
Italy
Facility Name
IRCCS Burlo Garofolo
City
Trieste
State/Province
Friuli Venezia Giulia
ZIP/Postal Code
34137
Country
Italy
Facility Name
Università degli studi di Padova - Centro Regionale Veneto di terapia del dolore e cure palliative pediatriche
City
Padova
State/Province
Veneto
ZIP/Postal Code
35100
Country
Italy

12. IPD Sharing Statement

Learn more about this trial

Needle Procedures Success Rate After Application of Ralydan vs EMLA in Children

We'll reach out to this number within 24 hrs